Leader Biomedical Group has forged an equity alliance with BioTiss GmbH, which will consolidate human musculoskeletal tissue processing at their facilities in Austria. The alliance will enable the company to further develop the eCOO^® Technologyplatform, which uses supercritical CO₂ to produce tissue products used in orthopaedic, dental, and wound care markets.
 
Through this partnership, Leader Biomedical will benefit from BioTiss’ technological capabilities and resources as well as being able to leverage their network of hospitals and tissue banks to market its products. It will also enable the company to enter the infection care market with the newly acquired rights to provide OSTEOmycin^® – the only antibiotic-impregnated allograft on the market processed with eCOO^® Technology.
 
“For more than a decade, I have been a firm believer in the potential of using supercritical CO₂ to produce superior quality allografts. With this partnership we will improve patient care by delivering a safer, more efficient product and I am extremely glad to have Leader Biomedical on board,” says Dr. Winkler, Managing Director of BioTiss GmBH.
 
The eCOO^® Technology platform applies supercritical CO₂ to produce safe, osteogenic grafts. It is a milder technique compared to conventional tissue processing, resulting in grafts exhibiting beneficial bio-molecular and mechanical characteristics such as avoidance of protein degradation, better cell adhesion, and superior tensile strength and torque. The platform is highly versatile and can be used to produce a variety of products such as bone void fillers, structural grafts, demineralised bone matrix (DBM), as well as connective and other soft tissue products.
 
“I am excited to welcome Dr. Winkler as a valuable partner in this alliance, which is an important milestone in the global roll out of eCOO^® Technology. It both expands Leader Biomedical’s allograft processing capacity in Europe and allows EMCM to focus on its core activities in the manufacturing of liquids, suspensions, and gels,” said Mr. Leo Liyeung, Executive Director of Leader Biomedical Group.
 
“This alliance is more than just a consolidation of our manufacturing activities; it will set into motion a new wave of development and innovation, which will enable us to better serve our customers and patients alike,” concludes Mr. Basil Babychan, Business Director of Leader Biomedical Group.
 
This new venture follows Leader Biomedical Group’s recent expansion into India and Brazil and demonstrates the company’s commitment to the development of the eCOO^® Technology platform.